Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07107607

Assessing Claims of Cannabis as an Anti-cancer Agent (CATA)

The purpose of the study is to find out how cannabis may help control cancer growth by reviewing medical records of patients who report cannabis helped treat their cancer.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Cancer Cancer (With or Without Metastasis) Chemically-Induced Disorders Marijuana Abuse Mental Disorders Neoplasms Substance-Related Disorders

Sex eligibility

All sexes

Study type

Observational

Primary location

HealthPartners Institute Cancer Research Center

Saint Louis Park, Minnesota, 55426, United States

About this study

The purpose of the study is to further assess how cannabis may help control cancer growth and attempt to validate such claims. To do this, the investigators will review medical records from consented patients who report that cannabis has helped to reduce or control growth of cancer by assessing prior cancer treatments and assessments (for example, cancer/tumor labs like prostate-specific antigen (PSA), cancer antigen (CA)-125, carcinoembryonic antigen (CEA) and radiology imaging reports such as computed tomography (CT) scan, positron emission tomography (PET)/CT scan, and magnetic resonance imaging (MRI)) as well as cannabis use details.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosed with cancer
  • have used any type of cannabis/marijuana, including those with cannabidiol (CBD) and/or tetrahydrocannabinol (THC) to treat their cancer
  • believe that cannabis has either stopped the tumor from growing and/or caused a cancer antigen blood marker to remain stable or cannabis has shrunken the tumor and/or caused reduction in a cancer antigen blood marker

Exclusion criteria

  • does not have cancer
  • has not used any type of cannabis/marijuana, including those with CBD and/or THC to treat their cancer
  • does not believe that cannabis has either stopped the tumor from growing and/or caused a cancer antigen blood marker to remain stable or cannabis has shrunken the tumor and/or caused reduction in a cancer antigen blood marker

Treatment and study plan

Primary outcomes

  1. To successfully complete Phase 2 by recruiting patients to consent with a simplified screening survey.

    Time frame: From enrollment start to the obtainment of cancer diagnosis and treatment details and cannabis use history from each consented patient, which is estimated to take up to 6 years.

    Successful completion of phase 2 of this survey study will include consenting 50 patients and obtaining their cancer and cannabis use details to validate anti-cancer claims.

Sponsors and collaborators

Lead sponsor

HealthPartners Institute

Other

Registry information

Official study title

Cannabis as an Anti-cancer Agent: A Review of Medical Records in Patients With Cancer to Assess Potential Anti-cancer Benefits From Using Cannabis

Acronym: CATA

Important dates

Study start
2021
Primary completion
2027
Study completion
2027
First posted
Aug 6, 2025
Registry last updated
May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.